ERBB2 and respiratory failure: Due to serious safety concerns, which arose after a single patient developed fatal acute respiratory failure following the administration of 1 × 1010 third generation HER2-CAR T cells, derived from the monoclonal antibody trastuzumab, in combination with IL-2 and lymphodepleting chemotherapy [22], we conducted our clinical study with HER2-CAR T cells without lymphodepletion.